Tenaya Therapeutics Outlines 2026 Strategy Including Regulatory Alignment for Gene Therapy Programs, Key Clinical Data Milestones, and Extended Funding Through Mid-2027

Reuters01-09
Tenaya <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Outlines 2026 <a href="https://laohu8.com/S/MSTR">Strategy</a> Including Regulatory Alignment for Gene Therapy Programs, Key Clinical Data Milestones, and Extended Funding Through Mid-2027

Tenaya Therapeutics Inc. has announced its strategic priorities and anticipated milestones for 2026. The company plans to build on the positive interim results from its TN-201 gene therapy program by providing longer-term follow-up data for Cohorts 1 and 2 from the MyPEAK-1 trial in adults with MYBPC3-associated hypertrophic cardiomyopathy during the first half of 2026. Additionally, Tenaya expects to report one-year Cohort 1 data and early Cohort 2 data from the RIDGE-1 study of TN-401 for PKP2-associated arrhythmogenic cardiomyopathy in the same timeframe. The company aims to pursue regulatory alignment on pivotal studies for both TN-201 and TN-401, with updates planned for the second half of 2026. Tenaya also intends to use recently raised capital to support the advancement of its clinical programs through these key milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622733-en) on January 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment